Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Dosage Changes In Patients With Long-term Botulinum Toxin Use For Laryngeal Dystonia

H. Birkent, N. Maronian, P. Waugh, A. Merati, D. Perkel, A. Hillel
Published 2009 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
OBJECTIVE: To investigate the dosage consistency of botulinum toxin injections in patients with long-term treatment for laryngeal dystonia. STUDY DESIGN: Chart review. SUBJECTS AND METHODS: Patients with laryngeal dystonia who had received at least 20 injections to the thyroarytenoid muscle were selected. Change of botulinum toxin dose, patient-reported effective weeks, and intervals between injections were investigated; data from the first five injections were excluded to eliminate initial dose titration. RESULTS: Fifty-five patients with an average follow-up of 12.5 years were identified. Mean dose of botulinum toxin was 2.37 ± 1.6 U at the sixth injection; there was a decrease in mean dose over time, which became statistically significant at the 13th injection with a mean dose of 2.02 ± 1.16 U. Mean duration of good effect and treatment intervals showed no significant change over time. CONCLUSION: Botulinum toxin dose needed for a constant response in treatment of laryngeal dystonia decreases over time, without any accompanying change in effective weeks and intervals.
This paper references
10.1016/j.otohns.2007.01.035
Relationship of botulinum dosage to duration of side effects and normal voice in adductor spasmodic dysphonia
C. Y. Chang (2007)
10.1177/000348949610500106
Long-Term Effects of Botulinum Toxin Injections in Spasmodic Dysphonia
B. Davidson (1996)
10.1002/1531-8249(200007)48:1<20::AID-ANA5>3.0.CO;2-U
Effects of botulinum toxin type A on intracortical inhibition in patients with dystonia
F. Gilio (2000)
10.1016/S0194-5998(99)70330-X
Muscle Fiber-Type Changes Induced by Botulinum Toxin Injection in the Rat Larynx
K. Inagi (1999)
10.3109/01658109209058127
'Ping-pong' gaze
Borodic Ge (1992)
Clinical and laboratory characteristics of focal laryngeal dystonia: study of 110 cases. Laryngoscope 1988;98:636–40
A Blitzer (1988)
10.1177/000348940010900215
Effects of Botulinum Toxin on Pathophysiology in Spasmodic Dysphonia
S. Bielamowicz (2000)
10.1523/JNEUROSCI.0375-08.2008
Long-Distance Retrograde Effects of Botulinum Neurotoxin A
F. Antonucci (2008)
10.1093/BRAIN/121.5.977
The corticomotor representation of upper limb muscles in writer's cramp and changes following botulinum toxin injection.
M. Byrnes (1998)
10.1097/00005537-200102000-00006
Botulinum Toxin: Basic Science and Clinical Uses in Otolaryngology
A. Blitzer (2001)
10.1016/J.NBD.2006.11.007
Acute and long-term effects of botulinum neurotoxin on the function and structure of developing extraocular muscles
Scott A. Croes (2007)
10.1016/S0306-4522(99)00512-6
Repeated stimuli for axonal growth causes motoneuron death in adult rats: the effect of botulinum toxin followed by partial denervation
C. M. White (1999)
[Progression of botulinum toxin type A dosage in craniocervical dystonias. An eight year comparative study].
A. Echeverría Urabayen (2004)
10.1016/S0022-510X(97)00151-2
The mechanism of action of Botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site
Nir Giladi (1997)
Part 2 : The study of laryngeal muscle activity in patients with laryngeal dystonia using multiple fine-wire electromyography
A. Hillel (2001)
10.1007/BF02850184
Longitudinal assessment of the dose consistency of botulinum toxin type a (BOTOX®) for cervical dystonia
A. Brashear (2005)
10.33588/RN.3806.2003433
Evolución de la dosis de toxina botulínica tipo A en distonías craneocervicales: Estudio comparativo a lo largo de ocho años
Amaya Echeverría Urabayen (2004)
Botulinum toxin (BOTOX) for the treatment of "spastic dysphonia" as part of a trial of toxin injections for the treatment of other cranial dystonias.
A. Blitzer (1986)
10.1177/000348940711601204
Long-Term Botulinum Toxin Dose Consistency for Treatment of Adductor Spasmodic Dysphonia
Paul K. Holden (2007)
10.1288/00005537-198802000-00015
Localized injections of botulinum toxin for the treatment of focal laryngeal dystonia (spastic dysphonia)
A. Blitzer (1988)
10.1016/S0967-5868(03)00020-1
Spasmodic dysphonia: clinical features and effects of botulinum toxin therapy in 169 patients—an Australian experience
S. Tisch (2003)
Pol - icy statement : botulinum toxin . Alexandria ( VA ) : American Academy of Otolaryngology – Head and Neck Surgery
A Blitzer (1997)
Effects of repeated botulinum toxin injections on orbicularis oculi muscle.
G. Borodic (1992)
10.1001/ARCHOTOL.126.4.533
Resistance to botulinum toxin injections for spasmodic dysphonia.
M. Smith (2000)
10.1288/00005537-198806000-00012
Clinical and laboratory characteristics of focal laryngeal dystonia: Study of 110 cases
Andrew Blitzer, Dds (1988)



This paper is referenced by
10.1017/S002221511400142X
Spasmodic dysphonia: a seven-year audit of dose titration and demographics in the Indian population.
N. Nerurkar (2014)
10.1097/MOO.0b013e32832aef6f
Treatment for spasmodic dysphonia: limitations of current approaches
C. Ludlow (2009)
10.1016/j.jvoice.2016.01.006
Botulinum Toxin Dosing Trends in Spasmodic Dysphonia Over a 20-year Period.
Arya W Namin (2017)
10.1016/j.jvoice.2016.09.022
Botulinum Toxin-A Dosing Trends for Adductor Spasmodic Dysphonia at a Single Institution Over 10 Years.
J. P. Bradley (2017)
Botulinum Toxin in Pediatric Neurology : Switching Lanes From Death to Life
E. Moawad (2015)
10.3389/fsurg.2017.00070
Long-term Dose Stability of OnabotulinumtoxinA Injection for Adductor Spasmodic Dysphonia: A 19-Year Single Institution Experience
P. Paddle (2017)
10.1111/coa.13678
Factors influencing long-term treatment response to botulinum toxin injection for spasmodic dysphonia.
Min Seong Kang (2020)
10.1016/j.jvoice.2013.10.024
Relationship of laryngeal botulinum toxin dosage to patient age, vitality, and socioeconomic issues.
D. Young (2014)
10.1177/1756285612447261
Current and future medical treatment in primary dystonia
C. Delnooz (2012)
10.1177/2333794X15590149
Botulinum Toxin in Pediatric Neurology
E. Moawad (2015)
10.11606/D.17.2013.TDE-10032014-111019
Avaliação vocal e da qualidade de vida em pacientes com distonia laríngea em tratamento com toxina botulínica
G. V. E. Rojas (2013)
10.1177/0194599820957608
Alternating Unilateral Versus Bilateral Injections of Botulinum Toxin for the Treatment of Adductor Spasmodic Dysphonia.
Seung Goo Lee (2020)
10.1590/S1516-18462013005000034
Tratamento médico e fonoaudiológico da disfonia espasmódica: uma revisão bibliográfica
E. Fabron (2013)
10.1016/j.toxicon.2018.10.006
OnabotulinumtoxinA for adductor spasmodic dysphonia (ADSD): Functional results and the role of dosage.
M. R. Marchese (2018)
10.1016/j.jvoice.2014.08.011
Factors influencing botulinum toxin dose instability in spasmodic dysphonia patients.
D. Rosow (2015)
10.1002/lary.24292
Voice disorders in the workplace: Productivity in spasmodic dysphonia and the impact of botulinum toxin
T. Meyer (2013)
10.1002/lary.20564
Influence of age and gender on dose and effectiveness of botulinum toxin for laryngeal dystonia
S. Vasconcelos (2009)
Semantic Scholar Logo Some data provided by SemanticScholar